Related Experiment Video
Updated: Feb 13, 2026

Author Spotlight: Evaluating the Adjuvant Efficacy and Safety of Angong Niuhuang Pill in Viral Encephalitis Treatment
Published on: April 19, 2024
Probiotics for pediatric atopic dermatitis: A systematic review and meta-analysis of randomized controlled trials
Muhammad Imran Arif1, Qianqian Dai1, Liang Ru1
1Department of Pediatrics, The First Affiliated Hospital of Xinjiang Medical University, Urumqi, Xinjiang, China.
Insights
Probiotics may improve quality of life for children with atopic dermatitis (eczema) but do not significantly improve clinical outcomes in the short term. Long-term effectiveness remains uncertain due to limited data.
Area of Science:
- Pediatric Dermatology
- Gastroenterology
- Microbiology
Background:
- Atopic dermatitis (eczema) is a common chronic inflammatory skin condition in children.
- Gut microbiota modulation via probiotics may influence eczema severity.
- Existing clinical trial data on probiotics for childhood atopic dermatitis is inconclusive.
Purpose of the Study:
- To compare the efficacy of probiotics versus placebo in children and adolescents diagnosed with eczema or atopic dermatitis.
- To evaluate the impact of probiotics on disease severity and quality of life.
Main Methods:
- A systematic review and meta-analysis of 13 randomized controlled trials.
- Searches conducted in PubMed/MEDLINE, Google Scholar, and Cochrane Library up to March 2025.
- SCORing Atopic Dermatitis (SCORAD) was the primary efficacy measure; statistical analysis used standard mean difference (SMD) with 95% confidence intervals (CI).
Main Results:
- Probiotics showed a statistically significant decrease in SCORAD after two months of treatment (SMD, -0.20 [95% CI, -0.36 to -0.03]; P = .02).
- Overall analysis indicated a significant reduction in SCORAD values with probiotics (SMD, -0.13 [95% CI, -0.26 to -0.01]; P = .04).
- Qualitative analysis suggested probiotics improve quality of life and clinical outcomes compared to placebo.
Conclusions:
- Probiotics may offer short-term improvements in patient-reported quality of life for atopic dermatitis.
- Clinical and anatomical outcomes did not show significant improvement with probiotics in the short term.
- The long-term clinical value of probiotics for atopic dermatitis is difficult to ascertain due to considerable SCORAD variability and a lack of long-term follow-up data.
Background:
Atopic dermatitis is a prevalent chronic inflammatory skin disease in children and the severity of the disease can be affected by modulation of gut microbiota through probiotics. Nonetheless, the clinical trial outcomes on the effectiveness of probiotics in child atopic dermatitis are inconclusive.
Objective:
We sought to compare the effects of using probiotics in comparison with placebo in children/adolescents with eczema/atopic dermatitis.
Methods:
We searched PubMed/MEDLINE, Google Scholar, and Cochrane Library from inception to March 2025. Statistical analyses were done in Review Manager version 5.4.1 (The Nordic Cochrane Centre, Copenhagen, Denmark). Pooling the trials using a fixed effect yielded standard mean difference (SMD) with 95% CI.
Results:
A total of 13 randomized controlled trials were used. SCORing Atopic Dermatitis (SCORAD) was used for assessing the efficacy of probiotics on atopic dermatitis. Subgroup analysis demonstrated a statistically nonsignificant difference in SCORAD within the first 2 months of the treatment (SMD, -0.04 [95% CI, -0.24 to 0.16]; P = .71; I 2 = 52%), whereas a statistically significant decrease in SCORAD was found in probiotics (SMD, -0.20 [95% CI, -0.36 to -0.03]; P = .02; I 2 = 77%) after 2 months. Overall, analysis indicated that probiotics decreased SCORAD values significantly (SMD, -0.13 [95% CI, -0.26 to -0.01]; P = .04; I 2 = 69%). Qualitative analysis showed that probiotics provide better quality of life and improve clinical and anatomical outcomes than placebo.
Conclusions:
Analysis found that probiotics can improve patient-reported quality of life in the short-term but not clinical results. However, SCORAD varies considerably over time and paucity of long-term follow-up data makes it difficult to determine the long-term clinical value of probiotics.
More Related Videos
Related Concept Videos
Random and Systematic Errors
Statistical Software for Data Analysis and Clinical Trials
Review and Preview
Percentiles are a type of fractile that partition data into...
Review and Preview
Trial and Error and Algorithm
Clinical Trials: Overview

